卡瑞利珠单抗联合化疗治疗老年NSCLC患者的效果分析

Effect Analysis of Carrilizumab Combined with Chemotherapy in the Treatment of Elderly Patients with NSCLC

目的:探究卡瑞利珠单抗联合化疗治疗老年非小细胞肺癌(NSCLC)患者的效果。方法:将本院96例老年NSCLC患者按照随机数字表法分为对照组(n=48例)和试验组(n=48例);对照组患者接受化疗治疗,试验组患者接受化疗+卡瑞利珠单抗治疗;比较两组患者临床疗效、血清相关指标水平以及不良反应情况。结果:治疗后,试验组患者临床疗效率高于对照组(P<0.05)、VEGF、MMP-9以及CY211水平低于对照组(P<0.05),两组患者不良反应发生率差异无统计学意义(P>0.05)。结论:卡瑞利珠单抗联合化疗治疗老年NSCLC,疗效显著,药物安全较高,值得临床推广。

Objective:To explore the efficacy of combination therapy with Carolizumab and chemotherapy in the treatment of elderly non-small cell lung cancer(NSCLC)patients.Methods:96 elderly NSCLC patients in our hospital were randomly divided into a control group(n=48 cases)and an experimental group(n=48 cases)using a random number table method.The control group patients received chemotherapy treatment,while the experimental group patients received chemotherapy and treatment with Carolizumab.Compare the clinical efficacy,serum related indicator levels,and adverse reactions between two groups of patients.Results:After treatment,the clinical treatment efficiency of the experimental group was higher than that of the control group(P<0.05),and the levels of VEGF,MMP-9,and CY211 were lower than those of the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion:Karelizumab combined with chemotherapy has a significant therapeutic effect and high drug safety in the treatment of elderly NSCLC,which is worthy of clinical promotion.